WO2003078409A1 - Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif - Google Patents
Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif Download PDFInfo
- Publication number
- WO2003078409A1 WO2003078409A1 PCT/JP2003/002635 JP0302635W WO03078409A1 WO 2003078409 A1 WO2003078409 A1 WO 2003078409A1 JP 0302635 W JP0302635 W JP 0302635W WO 03078409 A1 WO03078409 A1 WO 03078409A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methyl
- allergic
- compound
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
Definitions
- the present invention relates to carboxylic acid conjugates. More specifically, the present invention
- Prostaglandin D 2 (abbreviated as PGD 2 ) is known as a product of arakidonic acid cascade, and is known as an allergic disease, such as allergic monorhinitis, bronchial asthma, allergic conjunctivitis, etc. It is considered to be one of the chemical mediators involved in the disease.
- PGD 2 is mainly produced and released from mast cells, and released PGD 2 is known to exhibit bronchoconstriction, vascular hyperpermeability, vasodilation or constriction, promotion of mucus secretion, and platelet aggregation inhibitory action.
- PGD 2 is in 3 02635
- DP receptor antagonists bind to and antagonize their receptors, resulting in allergic diseases (eg, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, etc.), systemic mastocytosis , Systemic mast cell activation disorder, anaphylactic shock, airway constriction, deprived measles, eczema, acne, allergic bronchopulmonary aspergillosis, sinusitis, migraine, nasal polyps, irritable vasculitis, eosinophilia, contact Dermatitis, pruritic diseases (eg, atopic dermatitis, juniper, alargi conjunctivitis, alargi rhinitis, contact dermatitis, etc.), itch-related behavior (pulling, beating, etc.) Secondary to the disease (eg, cataract, retinal detachment, inflammation
- WO 86/05779 describes a general formula (T))
- ⁇ ⁇ represents a hydrogen atom, a phenyl group or a phenoxy group
- nT represents an integer of 3 to 10
- R 1T represents a hydrogen atom or a lower alkoxy group
- X 1T represents one CH 2 — Y 1T —
- ⁇ 1 ⁇ represents one ⁇ —, one S— or one ⁇ —
- ⁇ 2 ⁇ is one ⁇ —, one S— or one ⁇ —
- R 2T represents a hydrogen atom, a halo
- ⁇ 2 ⁇ has the formula 1 ⁇ 3 ⁇ — ⁇ 4 ⁇ — (wherein, ⁇ 3 ⁇ represents a single bond, 1 ⁇ —, 1 S— or 1 ⁇ ⁇ , and ⁇ 4 ⁇ may be interrupted by a sulfur atom in the middle. Represents an alkylene group of 1 to 6).
- DT represents a hydroxyl group, a lower alkoxycarbonyl group or the like. It is described that the compound represented by is useful as a drug for SRS-A (Slow reacting substance of anaphylaxis).
- prostaglandin receptors including subtypes, exist and each have different pharmacological effects. Thus, if a new compound that specifically binds to the DP receptor and has weak binding to other prostaglandin receptors can be found, it will not exhibit any other effects, so that it has few side effects. It may be a drug, and there is a need to find such a drug. Disclosure of the invention
- the present inventors have conducted intensive studies to find a compound that specifically binds and antagonizes the DP receptor. As a result, they have found that the carboxylic acid compound represented by the general formula (I) achieves this problem.
- the present invention has been completed.
- R 1 represents (1) a hydrogen atom, (2) a C 1-4 alkyl group, (3) a C 1-4 alkenyl, or (4) a benzyl group,
- R 2 represents (1) a halogen atom, (2) a C 1-6 alkyl group, (3) a C 1-6 alkoxy group, (4) a hydroxyl group, (5) a trihalomethyl group, (6) a cyano group, (7 ) A phenyl group, (8) a pyridyl group, (9) a nitro group, (10) a NR 6 R 7 group, or (ll) a C 1-4 alkyl group substituted by OR 8 ;
- R 3 represents (1) a halogen atom, (2) a C 1-6 alkyl group, (3) a C 1-6 alkoxy group, (4) a hydroxyl group, (5) a trihalomethyl group, (6) a cyano group, (7 ) A phenyl group, (8) a pyridyl group, (9) a nitro group, (10) —NR 6 R 7 group, or (11) —a C 1-4 alkyl group substituted with OR 8 ;
- R 6 and R 7 each independently represent a hydrogen atom or a C 1-4 alkynole group Represent,
- R 8 represents a C 1-4 alkyl group, a phenyl group, or a pyridyl group
- R 4 represents (1) a hydrogen atom, (2) a C 1-6 alkyl group, or (3) a benzyl group
- 5 is (1) a C1-6 alkyl group, (2) a C1-10 alkoxy group, (3) a C1-6 alkyl group substituted with a ⁇ 1-6 alkoxy group, (4) a halogen atom, (5) hydroxyl group, (6) trihalomethyl group, (7) nitro group, (8) —NR 9 R 10 group, (9) phenyl group, (10) phenoxy group, (11) oxo group, (12)
- R 9 and R 1Q each independently represent a hydrogen atom or a C 1-4 alkyl group
- R 11 represents a C 1-6 alkyl group
- (W) represents a C 5-12 monocyclic or bicyclic carbon ring, or a 5-12 membered monocyclic or bicyclic heterocyclic ring,
- G is (1) a C1-6 alkylene group containing 0 to 2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and (2) selected from a nitrogen atom, an oxygen atom and a sulfur atom.
- C2-6 alkylene group containing 0 to 2 hetero atoms, or (3) C2-6 containing 0 to 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom Represents an anolequinylene group
- ⁇ represents a C 5-12 monocyclic or bicyclic carbon ring, or a 5-12 membered monocyclic or bicyclic heterocyclic ring,
- n 0 or an integer of 1 to 4,
- n 0 or an integer of 1 to 4,
- i 0 or an integer from 1 to: L1.
- R 2 when m represents 2 or more, R 2 may be the same or different; when n represents 2 or more, R 3 may be the same or different; when i represents 2 or more, R 5 may be the same or different.
- examples of the C 1-4 alkyl group include a C 1-4 linear or branched alkyl group of methyl, ethyl, propyl, isopropyl, butyl, isoptyl, sec-butyl and tert-butyl.
- examples of the C1-6 alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isoptinole, sec-butyl, tert-butyl, pentyl, isopentinole, neopentinole, hexyl, and isohexynole groups.
- a C1-6 straight-chain or branched alkyl group is exemplified.
- the C 1-6 alkoxy group includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, isoptoxy, sec-butoxy, tert-butoxy, pentyloxy, isopench / reoxy, neopentynoleoxy, Examples thereof include a C 1-6 straight-chain or branched alkoxy group of hexyloxy and isohexyloxy groups.
- the C 1-10 alkoxy group includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, Hexyloxy, isohexyloxy, heptinolexy, octynoleoxy, nonyloxy, decyloxy C 1-10 linear or branched alkoxy groups.
- the C 2-6 acyl group includes ethanoyl, propanol, butanoyl, 2-methylpropanoyl, pentanoinole, 2-methylptanoyl, 3-methylbutanoyl, hexanoyl, 2-methylpentanoyl, 3-methylpentanoyl, 4-methylpentanoyl, 2-ethylpyranol, 2,3-dimethylbutanoyl C 1-6 straight chain And branched or branched acetyl groups.
- examples of the halogen atom include a fluorine, chlorine, bromine, and iodine atom.
- examples of the trihalomethyl group include a methyl group substituted with three halogen atoms.
- examples of the C1-4 alkylene group include a C1-4 linear or branched alkylene group such as a methylene, ethylene, propylene, isopropylene, butylene, or isobutylene group.
- the C2-4 alkenylene group includes a C2-4 straight-chain or branched alkylene such as a biylene, a probene, a 1- or 2-ptenylene group or a butagelen-group. And a diene group.
- the C2-4 alkynylene group includes a C2-4 straight-chain or branched alkynylene group such as an ethylene, a 1- or 2-propynylene, a 1- or 2-butynylene group. Is mentioned.
- the C 1-6 alkylene group containing 0 to 2 hetero atoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom includes methylene, ethylene, propylene, isopropylene, butylene, isopylene, pentylene , A hexylene group or other C 1-6 linear or branched alkylene group, or one or two of methylene, ethylene, propylene, isopropylene, butylene, isoptylene, pentylene, and hexylene groups
- NH— one
- examples of the C 2-6 alkenylene group containing from ⁇ to two hetero atoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom include vinylene, propylene, 1- or 2-ptenylene, C2-6 linear or branched alkenylene groups such as butagenylene, pentenylene, hexenylene, etc., or vinylene, propenylene, 1- or 2-butenylene, ptagenylene, pentenylene
- the C 2-6 alkynylene group containing 0 to 2 hetero atoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom includes ethynylene, 1- or 2-propynylene, C2-C6 linear or branched alkynylene groups such as 2-pentynylene, pentynylene, hexidylene, etc., or ethynylene, 1- or 2-propynylene, 1- or 2-petinylene 1 or 2 carbon atoms in ren, pentylene, hexylene or hexenylene are nitrogen
- the C 5-12 monocyclic or bicyclic carbocyclic ring includes a C 5-12 monocyclic or bicyclic carbocyclic aryl, a partially or wholly saturated carbon ring.
- Examples include perhydroindene, indane, naphthalene, dihydronaphthalene, tetrahydronaphthalene, and perhydronaphthalene.
- the 5- to 12-membered monocyclic or bicyclic heterocyclic ring is selected from 1 to 4 nitrogen atoms, 1 to 2 oxygen atoms and Z or 1 to 2 sulfur atoms. And a 5- or 12-membered monocyclic or bicyclic heterocyclic aryl containing a hetero atom to be obtained, and a partially or wholly saturated heterocyclic ring.
- examples of the C 5-6 saturated carbocyclic ring include cyclopentane and cyclic hexane ring.
- Examples of the 5- to 6-membered saturated heterocycle containing 2 oxygen atoms and / or 1 sulfur atom include, for example, pyrrolidine, imidazolidine, virazolidine, piperidine, piperazine, perhydropyrimidine, perhydropyridazine , Tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, tetrahydrooxazole (oxazolidine), tetrahydroisoxazole (isoxazolidin), tetrahydrothiazole (thiazolidine), tetrahydroisothiazole (isothiazolidine), Tetrahydrooxazine, tetrahydrothiazine, morpholine, thiomorpholine, oxathiane, dioxolan, dioki And a sun ring.
- examples of the C 5-6 carbon ring include cyclopentane, cyclohexane, cyclopentene, cyclohexene, cyclopentadiene, cyclohexadiene, benzene ring and the like.
- examples of the 5- to 6-membered heterocyclic ring containing 1 to 2 nitrogen atoms, 1 to 2 oxygen atoms and Z or 1 sulfur atom include, for example, pyrrole, imidazone, pyrazonole , Pyridine, pyrazine, pyrimidine, pyridazine, furan, pyran, thisaifen, thiopyran, oxazole, isooxazole, thiazole, isothiazole, oxazine, thiazine, pyrroline, pyrrolidine, imidazoline, imidazolidin, pyrazoline, pyrazoline, pyrazoline Tetrahydropyridine, piperidine, dihydrovirazine, tetrahydrovirazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, parahydropyrimidine, dihydropyridazine, tetrahydropyridazine
- alkyl, alkoxy, and alkylene groups include straight and branched ones.
- isomerism in double bonds, rings and fused rings E, Z, cis, trans
- isomers due to the presence of asymmetric carbon R, S, j3 ', enantiomer, diastereomer
- optically active optically active D, L, d
- D optically active optically active
- the compound of the present invention is converted into a pharmaceutically acceptable salt by a known method.
- the pharmaceutically acceptable salt is preferably a non-toxic, water-soluble salt.
- Suitable salts include, for example, salts of alkali metals (potassium, sodium, lithium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), ammonium salts (tetramethylammonium salt, tetrabutylammonium salt) Salt, etc.), organic amines (triethylamine, methylamine, dimethylamine, cyclopentylamine, benzyl ⁇ amine, phenetinoleamine, piperidine, monoethanolanolamine, diethanolamine, tris (hydroxymethyl) Salts of methylamine, lysine, arginine, ⁇ -methyl-D-glucamine, etc., acid adduct salts (inorganic acid salts (hydrochloride, hydrobromide, hydroiodide, s
- the solvate is non-toxic and water-soluble.
- Suitable solvates include, for example, solvates such as water and alcoholic solvents (such as ethanol).
- R 1 is preferably a hydrogen atom, C:!-4 alkyl group or benzyl, more preferably a hydrogen atom or C 1-4 alkyl group.
- R 2 is preferably a halogen atom, Cl-6 alkyl group, Cl-6 alkoxy group, hydroxyl group, trihalomethyl group, cyano group, phenyl group, pyridyl group, nitro group, NR 6 R 7 group And more preferably a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or a hydroxyl group.
- R 3 is preferably a halogen atom, a Cl-6 alkyl group, a Cl-6 alkoxy group, a hydroxyl group, a trihalomethyl group or a cyano group, more preferably a halogen atom, Cl-6 alkyl. Group, Cl-6 alkoxy group or hydroxyl group.
- R 8 is preferably a C 1-4 alkyl group or a phenyl group.
- R 4 is preferably a hydrogen atom, a C1-4 alkyl group or benzyl, and more preferably a hydrogen atom or a C1-4 alkyl group.
- R 5 is preferably a C 1-6 alkyl group, a Cl-10 alkoxy group, a halogen atom, a hydroxyl group, a trihalomethinole group, a phenyl group, or a cyano group, more preferably It is a C1-6 alkyl group, a C1-10 alkoxy group, or a halogen atom.
- Preferred rings for (W) are C5-6 monocyclic carbocycles, or 5-6 membered containing 1-2 nitrogen atoms, 1-2 oxygen atoms Z or 1 sulfur atom. It is a monocyclic heterocycle.
- Specific preferred rings include cyclopentane, cyclohexane, benzene, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, furan, pyran, thiophene, thiovirane, oxazole, isooxazole, thiazole, isothiazole, Pyrrolidine, imidazolidine, piperidine and piperazine rings, with a benzene or pyridine ring being more preferred. Particularly preferably, it is a C5-6 monocyclic carbocyclic ring.
- G is preferably (1) a C 1-6 alkylene group containing 0 to 2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, (2) C 2-6 Alkenylene group, or (3) C2-6 alkynylene group, more preferably (1) C1-6 containing 0-2 heteroatoms selected from nitrogen atom, oxygen atom and sulfur atom
- An alkylene group, (2) a C2-4 alkenylene group, or (3) a C2-4 alkynylene group particularly preferably (1) a C1-4 alkylene group, (2) a C2-4 alkenylene group, or (3) C2-4 alkynylene group.
- A is a C 5-6 saturated carbocycle, or 1-2 nitrogen atoms, 2 C
- ⁇ ′ represents a C 5-6 carbocyclic ring or a 5- to 6-membered heterocyclic ring containing 1-2 nitrogen atoms, 1-2 oxygen atoms and Z or one sulfur atom.
- a 5- to 6-membered saturated heterocyclic ring containing one sulfur atom and more preferably a 5- to 6-membered ring containing 1-2 nitrogen atoms and / or or 1-2 oxygen atoms
- morpholine, dioxane, oxathian, tetrahydrofuran, pyrrolidine, tetrahydrooxazole (oxazolidin), and imidazolidine ring are preferable, and morpholine, tetrahydrofuran, and pyrrolidine ring are particularly preferable.
- Preferred rings for I: B) are C 5-6 carbocycles or 5-6 membered heterocycles containing 1-2 nitrogen atoms and / or 1-2 oxygen atoms, more preferably Is a C 5-6 carbocycle or a 5-6 membered heterocycle containing 1-2 nitrogen atoms.
- cyclopentane, cyclohexane, cyclopentadiene, benzene, pyridine, pyrazine, pyrimidine, pyridazine, oxazine, piperidine, piperazine ring are preferable, and cyclohexane, benzene, pyridine, virazine, pyrimidine are more preferable. It is a ring, and a benzene ring is particularly preferred.
- ⁇ ⁇ ⁇ is preferably a dihydrobenzozoxazine, benzodioxane, benzoxoxathiane, dihydrobenzozofuran or indoline ring, more preferably a dihydrobenzozoxazine, dihydrobenzozofuran, or an indoline ring, particularly preferably dihydrobenzozoxazine.
- n is preferably 0, 1 or 2.
- n is preferably 0, 1 or 2.
- i is preferably 0 or an integer of 1 to 5.
- Specific compounds of the present invention include the compounds shown in Tables 1 to 35, the compounds shown in Examples, and pharmaceutically acceptable salts thereof.
- H -CH2- 2-CH 3 6- F 39 H -CH2- 2-CM3 5-r 6-F 40 4-CH3 -co- distrust or -CH3 -S0 2 - 2-CH3 6-F 41 -CH3 -S02- 2-CH3 5-F
- the compound of the present invention is a compound that specifically binds to the DP receptor and weakly binds to other prostaglandin receptors. Further, the compound of the present invention is a compound having excellent solubility. Such properties are important in developing as pharmaceuticals, the compounds of the present invention is considered to Les, Ru and blessed with conditions to be a very good drugs [The Merck Manual of Diagnosis and Therapy (17 th Ed), Merck & Co. Publishing].
- the compound of the present invention represented by the general formula (I) can be produced, for example, according to the following method.
- R 1A represents a C 1-4 alkyl group, C 2-4 alkenyl or benzyl group, and the other symbols have the same meanings as described above.
- R 2 one 1 have the same meanings as R 2, also city hydroxyl group included in the group represented by R 2 one 1 or amino groups, are protected when protection is required, R 4 one 1 represents a hydrogen atom, compounds and other symbols indicated the same meanings as described above in to.) I Table, or formula (II-2)
- R 4 - 2 represents a C 1 to 6 alkyl group or a benzyl group, and the other Symbol the same meanings as described above.
- E 1 represents an COOH or a S0 3 H, R 3 - 1, and R 5 - 1, a force respectively represent the same meanings as R 3 and R 5 S, R 3 one 1 and R 5 one
- the hydroxyl group or amino group contained in the group represented by 1 is protected if necessary, and the other symbols have the same meanings as described above.
- the compound can be produced by subjecting the compound to a chemical reaction and, if necessary, to a deprotection reaction.
- the method using an acid halide is, for example, a method in which a carboxylic acid is used in an organic solvent (chloroform, dichloromethane, dimethyl ether, tetrahydrofuran, dimethyloxetane, toluene, or the like) or in the absence of a solvent to form an acid halide agent (oxalinolate). Chloride and thioyrk-mouth ride) at a temperature of 20 ° C.
- a phase transfer catalyst tetrabutylammonium chloride, triethynolbenzylammonium chloride, tri-n-octymethyl
- Alkaline aqueous solution aqueous sodium bicarbonate or sodium hydroxide
- quaternary ammonium salts such as luammonium chloride, trimethyldecylammonium mouthride, tetramethylammonium bromide, etc.
- the method of using a mixed acid anhydride is, for example, a method in which a carboxylic acid is dissolved in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.) or in the absence of a solvent in the presence of a base (pyridine, triethylamine, dimethylaniline, dimethyl).
- Acid halides such as pivaloyl chloride, tosyl or mesyl chloride
- acid derivatives such as ethyl ethyl formate or isobutyl chloroformate
- a method using a condensing agent is, for example, a method in which a carboxylic acid and an amine are converted into a base (pyridine, pyridine, or the like) in an organic solvent (such as chloroform, dichloromethane, dimethinoleformamide, getyl ether, or tetrahydrofuran) or without a solvent.
- a base pyridine, pyridine, or the like
- an organic solvent such as chloroform, dichloromethane, dimethinoleformamide, getyl ether, or tetrahydrofuran
- condensing agent (1,3-dicyclohexylcarpoimide (DCC), 1-ethynole-1- [3- (dimethylamino) propyl) ] Carbodimid (E DC), 1, 1'-Carbonyl diimidazole (CD I), 2-Chloro-1-methylpyridinium iodine, 1-propanephosphomc acid cyclic anhydride PPA ) With or without 1-hydroxybenztriazole (HOBt) at 0-40 ° C. Is Nawa.
- the deprotection reaction by alkali hydrolysis is performed, for example, in an organic solvent (methanol, tetrahydrofuran, dioxane, etc.), alkali metal hydroxide (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), alkali
- the reaction is carried out at a temperature of 0 to 40 ° C using an earth metal hydroxide (barium hydroxide, calcium hydroxide, etc.) or carbonate (sodium carbonate, potassium carbonate, etc.) or an aqueous solution or a mixture thereof. .
- the deprotection reaction under acid conditions is performed, for example, in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate, anisol, etc.) in an organic acid (acetic acid, trifluoroacetic acid, methanesulfonic acid, p-tosylic acid). ) Or in an inorganic acid (hydrochloric acid, sulfuric acid, etc.) or a mixture thereof (hydrogen bromide / acetic acid, etc.) at a temperature of 0 to 100 ° C.
- Deprotection reactions by hydrogenolysis include, for example, solvents (ether (tetrahydrofuran, dioxane, dimethoxytan, getyl ether, etc.)), phenolic (methanolone, ethanolol, etc.), benzene (benzene , Toluene, etc.), ketones (acetone, methylethyl ketone, etc.), nitriles (acetonitrile, etc.), amides (dimethylformamide, etc.), water, ethyl acetate, acetic acid or a mixed solvent of two or more of them Medium) in the presence of a catalyst (palladium-carbon, palladium black, palladium hydroxide, platinum oxide, Raney nickel, etc.) The reaction is carried out at a temperature of 0 to 200 ° C. in a hydrogen atmosphere under normal pressure or under pressure or in the presence of ammonium formate.
- solvents ether (tetrahydrofuran, diox
- the deprotection reaction of the silyl group is carried out, for example, by using tetrabutylammonium fluoride in a water-miscible organic solvent (tetrahydrofuran, acetonitrile, etc.) at 0 to 40 ° C. Done at temperature.
- a water-miscible organic solvent tetrahydrofuran, acetonitrile, etc.
- the deprotection reaction using a metal is carried out, for example, in an acidic solvent (acetic acid, a buffer solution of pH 4.2 to 7.2 or a mixture thereof and an organic solvent such as tetrahydrobran) in the presence of powdered zinc, It is carried out at a temperature of 0 to 40 ° C with or without sonication.
- an acidic solvent acetic acid, a buffer solution of pH 4.2 to 7.2 or a mixture thereof and an organic solvent such as tetrahydrobran
- the deprotection reaction using a metal complex may be performed, for example, in an organic solvent (dichloromethane, dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitril, dioxane, ethanol, etc.), water or a mixed solvent thereof.
- organic solvent dichloromethane, dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitril, dioxane, ethanol, etc.
- Trapping reagents triptyltin hydride, triethylsilane, dimedone, morpholine, getylamine, pyrrolidine, etc.
- organic acids acetic acid, formic acid, 2 -ethylinohexanoic acid, etc.
- Z or organic acid salts sodium 2-ethylhexanoate
- Metal complexes tetrakistriphenylphosphine palladium (0), bis (trif), in the presence or absence of phosphine-based reagents (such as triphenylinolephosphine) in the presence of Enylphosphine) palladium (II), para-acetate Um (II), using a Tris chloride (triphenyl phosphinite emissions) rhodium (I) etc.), at a temperature of 0-4.
- hydroxyl-protecting group examples include a methyl group, a trityl group, a methoxymethyl (MOM) group, a 1-ethoxyxyl (EE) group, a methoxyethoxymethyl (MEM) group, a 2-tetrahydrobilanyl (THP) group, and a trimethylsilyl group.
- TMS Triethylsilyl
- TDMS t-butyldimethylsilyl
- TDPS t-butyldiphenylsilyl
- acetyl (Ac) group piperoyl group
- benzoyl group benzyl (Bn ) Group
- p-me Examples include a toxicobenzyl group, an aryloxycarbonyl (A1 oc) group, and a 2,2,2-trichloroethoxycarbonyl (Troc) group.
- Examples of the protecting group for the amino group include benzyloxycarbonyl group, t-butoxycarbonyl group, aryloxycarbonyl (A1 oc) group, 1-methyl-1- (4-biphenyl) ethoxycaslevonyl ( B poc) group, trifluorophenol acetyl group, 9-fluorenylmethoxycarbonyl group, benzyl (Bn) group, p-methoxybenzyl group, benzyloxymethyl (BOM) group, 2- (trimethylsilyl) ethoxymethyl ( SEM) group.
- benzyloxycarbonyl group t-butoxycarbonyl group
- aryloxycarbonyl (A1 oc) group 1-methyl-1- (4-biphenyl) ethoxycaslevonyl ( B poc) group
- trifluorophenol acetyl group 9-fluorenylmethoxycarbonyl group
- the protecting group for the hydroxyl group or the amino group is not particularly limited as long as it is a group that can be easily and selectively eliminated, in addition to the groups described above.
- the deprotection reaction can be carried out by this method described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1999.
- the reductive amination reaction is known.
- a reducing agent sodium triacetoxyborohydride, sodium cyanoborohydride
- an organic solvent diichloroethane, dichloromethane, dimethylformamide, acetic acid mixture, etc.
- Sodium borohydride, etc. at a temperature of 0 to 40 ° C.
- Z represents a leaving group or a hydrogen atom, and the other symbols have the same meanings as described above.
- the etherification reaction is known, and when a compound represented by the general formula (VI) in which Z is a leaving group is used, for example, an organic solvent (dimethylformamide, dimethylenolesnorreoxide, chlorohonolem, dichloromethane, jeti / Alkali metal hydroxides (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), alkaline earth metal hydroxides (valium hydroxide, sodium hydroxide, etc.) In the presence of calcium hydroxide, etc., carbonates (cesium carbonate, sodium carbonate, potassium carbonate, etc.) or hydrides of alkali metals (sodium hydride, hydrogenation power, etc.) or their aqueous solutions or mixtures of these It is carried out by reacting at 0 ° C to reflux temperature.
- an organic solvent dimethylformamide, dimethylenolesn
- an azo compound getyl azodicarboxylate
- an organic solvent dichloromethane, getyl ether, tetrahydrofuran, acetonitrile, benzene, toluene, etc.
- Diisopropyl azodicarboxylate 1,1,1- (azodicarbonyl) dipiperidine, 1,1'-azobis (N, N-dimethinoleformamide), etc.
- phosphine compounds triphenylinolephosphine, tributylphosphine, trimethylphosphine
- N-alkylation reactions include, for example, carbonates (eg, cesium carbonate, sodium carbonate) in an organic solvent (dimethylformamide, dimethinoles noreoxide, chlorohonolem, dichloromethane, methyl alcohol, tetrahydrofuran, etc.). , Potassium carbonate, etc.) in the presence of (Cl-6) alkyl halide or benzyl halide at 0 to 40 ° C.
- carbonates eg, cesium carbonate, sodium carbonate
- organic solvent dimethylformamide, dimethinoles noreoxide, chlorohonolem, dichloromethane, methyl alcohol, tetrahydrofuran, etc.
- Potassium carbonate, etc. in the presence of (Cl-6) alkyl halide or benzyl halide at 0 to 40 ° C.
- a solvent such as an organic solvent (dichloromethane, dimethyl ether, tetrahydrofuran, acetonitrile, benzene, toluene, etc.), Azo compounds (ethyl azodicarboxylate, diisopropyl azodicarboxylate, 1,1 '-(azodicarbon) dipiperidine, 1,1'-azobis (N, N-dimethylformamide), etc.) and phosphine compounds (triphenylinolephosphine, triphenyl (C1-6) alkyl alcohol or benzyl alcohol at 0 to 60 ° C. in the presence of butylphosphine, trimethylphosphine, polymer support triphenylphosphine and the like.
- organic solvent dichloromethane, dimethyl ether, tetrahydrofuran, acetonitrile, benzene, toluene, etc.
- Azo compounds ethyl azo
- the compound represented by the general formula (IA) is obtained by subjecting the compound represented by the general formula (IA) to a deprotection reaction of a protecting group for a carboxyl group, and, if necessary, The compound can be produced by subjecting a protecting group for a hydroxyl group or an amino group to a deprotection reaction.
- the deprotection reaction by alkali hydrolysis is performed, for example, in an organic solvent (eg, methanol, tetrahydrofuran, dioxane) in the presence of an alkali metal hydroxide (eg, sodium hydroxide, potassium hydroxide, lithium hydroxide).
- an alkali metal hydroxide eg, sodium hydroxide, potassium hydroxide, lithium hydroxide.
- alkaline earth metal hydroxides barium hydroxide, calcium hydroxide, etc.
- carbonates sodium carbonate, potassium carbonate, etc.
- the deprotection reaction under acid conditions is performed, for example, by using an organic acid (acetic acid, acetic acid, acetic acid, anisol, etc.) in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate, anisol, etc.). Trifluoroenoacetic acid, methanesulfonic acid, p-tosylic acid, etc.), or inorganic acid (hydrochloric acid, sulfuric acid, etc.) or a mixture of these (hydrobromic acid, etc.) at a temperature of 0 to 1 oo ° c .
- Deprotection reactions by hydrogenolysis include, for example, solvents (such as ether (tetrahydrofuran, dioxane, dimethoxetane, and getyl ether)), alcohols (such as methanol and ethanol), and benzenes (such as benzene and toluene).
- solvents such as ether (tetrahydrofuran, dioxane, dimethoxetane, and getyl ether)
- alcohols such as methanol and ethanol
- benzenes such as benzene and toluene
- Ketones acetone, methyl ethyl ketone, etc.
- nitriles acetonitrile, etc.
- amides dimethylformamide, etc.
- water ethyl acetate, acetic acid, or a mixture of two or more of them
- a catalyst palladium-carbon, palladium black, palladium hydroxide, platinum oxide, Raney nickel, etc.
- ammonium formate at 0 to 200 ° C Done at temperature.
- the deprotection reaction using a metal is performed, for example, in an acidic solvent (acetic acid, a buffer solution of pH 4.2-7.2 or a mixture thereof and an organic solvent such as tetrahydrofuran) in the presence of powdered zinc, Performed at a temperature of 0-40 ° C with or without sonication
- an acidic solvent acetic acid, a buffer solution of pH 4.2-7.2 or a mixture thereof and an organic solvent such as tetrahydrofuran
- the target compound of the present invention can be easily produced by properly using these deprotection reactions.
- the deprotection reaction of a protecting group for a hydroxyl group or an amino group can be carried out in the same manner as described above.
- the compounds represented by the general formulas (II-1) and (II-2) can be produced by the method represented by the following reaction scheme 1.
- X represents a halogen atom
- R 4 _ 3 is a hydrogen atom
- 1-5 Represents a alkyl group or a phenyl group, and the other symbols have the same meanings as described above.
- the reaction product is purified by conventional purification means, for example, distillation under normal or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin-layer chromatography, or column chromatography. It can be purified by a method such as chromatography, washing, or recrystallization. Purification may be performed for each reaction or may be performed after completion of several reactions.
- conventional purification means for example, distillation under normal or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin-layer chromatography, or column chromatography. It can be purified by a method such as chromatography, washing, or recrystallization. Purification may be performed for each reaction or may be performed after completion of several reactions.
- membrane fraction prepared in a polyethylene tube (Membrane protein content: 40 to 150 g), Atsushi buffer (1 mmo 1 / L EDTA, 5 mmo 1 / L Mg 2+ and 10 mmo 1 / L Mn 2 + Including 25 mm o 1 / L HE PES -NaOH, pH 7.4) 100 ⁇ L, medium (dimethylsulfoxide, DMSO) or 1 ⁇ L of the compound of the present invention (final concentration of DMSO: 0.5%) and 10 nmo 1 / L [ 3 : «] —? After adding 00 2 to 50 ° (final concentration: 2.5 nmol 1 / L), the mixture was incubated at room temperature.
- DMSO dimethylsulfoxide
- the non-specific binding group was added 2 mm o 1 / Shino PGD 2 in place of the medium (final concentration of PGD 2: 10 / zmo 1 / L). 20 minutes later, Add 1 mL of ice-cold washing buffer (10 mm o 1 / L Tris-HC 1 buffer containing 0.01% ⁇ serum albumin (BSA) and 10 Ommo 1 / LNaCl, H7. 4) was added to the mixture to stop the reaction. Immediately under reduced pressure and suction filtration, the membrane fraction was trapped on glass fiber filter paper (GFZB). The membrane fraction on the glass fiber filter was washed once with about 2 mL of the washing buffer, and the glass fiber filter was dried. The dried glass fiber filter was placed in a glass vial, and the liquid scintillation cocktail was added. After the addition, the radioactivity was measured with a liquid scintillation counter.
- GFZB glass fiber filter paper
- [3 H] - specific binding to PGD 2 in DP receptor was calculated by subtracting the radioactivity of non-specific binding group from the radioactivity of the group other than the non-specific binding group. Calculating the inhibition rate according to the invention of compounds of specific binding of [3 H] -P GD 2 in the medium group Oyopi present invention compounds, IC 5 estimated.
- the Ki value dissociation constant of the compound of the present invention was calculated from the value (the concentration of the compound of the present invention required to inhibit the specific binding amount in the medium group by 50%) according to the following formula.
- [3 H] K d value of -PGD 2 is in accordance with the above method, various concentrations [3 H] - P GD 2 calculates the specific binding upon addition, was estimated from the non-linear regression analysis . From the results of the above measurements, the compounds of the present invention were less than 10 mo! ⁇ Values were found to bind strongly to the DP receptor.
- the reaction solution was frozen once (80 ° C), thawed, the cells were detached with a scraper, and centrifuged at 13,000 rpm for 3 minutes. The supernatant was collected, and the cAMP concentration in the supernatant was measured. The measurement was carried out by a radioimmunoassay method using an AMP assay kit (cAMP assay kit) (manufactured by Amersham).
- cAMP assay kit manufactured by Amersham
- 125 ⁇ l of the supernatant obtained above was added to the buffer solution of [ 125 I] c AMP assay kit to make 500 / L, and this was added to 0.5 mo 1 / L tri-n-octylamine (tri-n- octylamine), and extract the TCA into the layer of the lip of the mouth, then use the aqueous layer as a sample and sample according to the method described in the [ 125 I] c AMP Atssay kit. The amount of cAMP in it was quantified.
- the compound of the present invention has an IC 5 of 10 // mo 1 ZL or less. By value, it was found to strongly antagonize the DP receptor. The toxicity of the compound of the present invention represented by the general formula (I) was sufficiently low, and it was confirmed that the compound was sufficiently safe for use as a medicament. Industrial applicability
- the compound of the present invention represented by the general formula (I) binds to and antagonizes a DP receptor, so that a disease caused by activation of the DP receptor, for example, an allergic disease (eg, allergic rhinitis, allergic conjunctivitis, Atopic dermatitis, bronchial asthma, food allergy, etc.), systemic mastocytosis, systemic mast cell activation disorder, anaphylactic shock, airway constriction, juniper measles, eczema, acne, allergic bronchopulmonary Aspergillosis, sinusitis, migraine, nasal polyps, irritable vasculitis, eosinophilia, contact dermatitis, itchy diseases (eg atopic dermatitis, juniper measles, allergic conjunctivitis, allergic Rhinitis, contact dermatitis, etc.), and diseases secondary to itch-related activities (eg, grabbing, beating, etc.) (eg, cataract,
- those having a weak binding to a compound other than the DP receptor do not exhibit other effects, and thus may be a drug with less side effects.
- the compound may be administered as a concomitant drug in combination with other drugs to reduce the side effects of the compound.
- the concomitant drug of the compound of the present invention represented by the general formula (I) and another drug may be administered in the form of a combination preparation in which both components are combined in one preparation, or in the form of a separate preparation. May be taken.
- simultaneous administration and administration at different times are included.
- the administration by the time difference may be performed by administering the compound of the present invention represented by the general formula (I) first and then administering another drug, or administering the other drug first,
- the compound of the present invention represented by may be administered later.
- Each administration method may be the same or different.
- Diseases which exert the preventive and / or therapeutic effects by the above concomitant drug are not particularly limited, and are diseases which complement and / or enhance the preventive and / or therapeutic effects of the compound of the present invention represented by the general formula (I). If you can! / ,.
- agents for preventing or supplementing the effect of the compound of the present invention represented by the general formula (I) on allergic rhinitis or for complementing or enhancing the effect of Z include, for example, antihistamines, mediator release inhibitors, Thromboxane synthase inhibitor, topompoxane A 2 receptor antagonist, leukotriene receptor antagonist, steroid, ⁇ - adrenergic receptor stimulant, xanthine derivative, anticholinergic agent, nitric oxide synthase inhibitor, etc.
- drugs for preventing and / or enhancing or preventing the effect of the compound of the present invention represented by the general formula (I) on allergic conjunctivitis include, for example, leukotriene receptor antagonists, antihistamines, Mediators Examples include release inhibitors, nonsteroidal anti-inflammatory drugs, prostaglandins, steroids, nitric oxide synthase inhibitors and the like.
- antihistamines examples include ketotifen fumarate, mequitazine, azelastine hydrochloride, oxatomide, terfenadine, emedastin fumarate, epinastine hydrochloride, astemizole, ebastine, cetirizine hydrochloride, bepota Stin, fexofenadine, rat latazine, rat latadine, olopatadine hydrochloride, TAK—427, ZCR-2060, NI P—530, mometasoneph mouth ate, mizolastine, BP—294, andlast, auranofin, ataribasin Chin and the like.
- mediator release inhibitor examples include tranilast, sodium cromoglycate, amlexanox, revilinast, ibudilast, dazanolast, and mirolast potassium.
- thromboxane synthase inhibitor examples include ozadarel hydrochloride, imitrodust sodium, and the like.
- the thromboxane A 2 receptor antagonists for example, seratrodast, llama tropane, domitroban pan calcium hydrate, Ru mentioned KT 2-962 and the like.
- leukotriene receptor antagonists examples include pranlukast hydrate, montelukast, zafirlukast, MCC—847, CA-757, CS—615, YM-158, L—740515, CP—195494, LM—1484, RS_635 , A-93178, S_36496, BIIL-284, ONO-4057 and the like.
- topical drugs include clobetasol propionate, diflorazone acetate, fluocinodo, mometasone furoate, betamethasone dipropionate, betamethasone dipropionate, betamethasone butyrate, betamethasone valerate, difluprednate, pudesonide , Diflucortron valerate, amcinodid, halcinonid, dexamethasone, dexamethasone propionate, dexamethasone valerate, dexamethasone acetate, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone butyrate, depromethionate propionate Don, prednisolone acetate valerate, fluocino mouth nacetonide, beclomethasone propionate, triamcinolone acetonide, flumethasone pivalate, Alclomethasone propionate, clobetasone butyrate
- Oral drugs and injections include cortisone acetate, hydrocortisone, hydroconoresone sodium hydrocortisone, sodium hydrocortisone sodium succinate, cortisone sodium in the oral cavity, prednisolone, prednisolone acetate, prednisolone sodium succinate, prednisolone butyl acetate, Prednisolone sodium phosphate, halopredone acetate, methinoleprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, triamcinolone, triamcinolone acetate, triamcinolone acetonide, dexamethasone, dexamethasone dexamethasone, sodium dexamethasone , Paramethasone acetate, betamethasone, etc.
- Inhalants include methoxazone propionate, flutizonzonate propionate, budesonide, flunisolide, triamcinolone, ST-126P, cyclesonide, dexamethasone paromichionate, mometasone furan carbonate, plasterone. Sulfonate, deflazacort, methylprednisolone reptanate, methylprednisolone sodium succinate and the like.
- xanthine derivative examples include aminobuline, theophylline, doxophylline, sipamphyrin, diprofylline and the like.
- anticholinergic agents for example, iprat bromide, oxitropium bromide, furtium bromide, simetropium bromide, temiverine, pium bromide, pivalium tiobromide, revatropate (UK-112) And the like.
- Non-steroidal anti-inflammatory drugs include, for example, sazapyrine, sodium salicate, aspirin, aspirin; dialuminate, diflunisal, indomethacin, suprofen, fenamate, dimethylisopropylazulene, bufexamac, fuerbinac, diclofenac, tolmetinnat Lium, crinolyl, fenbufen, napmetone, progourmetasin, indomethacin buarnesyl, acemetacin, progomeratasin maleate, ampfenac sodium, mofuezorak, etodolac, ibuprofen, ipuprofen piconore, naproxen, flurubiine Profen, fenoresoleb oral fenaxetil, ketoprofen, phenoprofen canolecidium, thiaprofen, oxaprozin, pranoprofen, lox
- PG receptors include PGE receptor (EP1, EP2, EP3, EP4), PGD receptor (DP, CRTH2), PGF receptor (FP), PGI receptor (IP), TX receptor (TP) And the like.
- the weight ratio of the compound represented by formula (I) to the other drug is not particularly limited.
- Other drugs may be administered in any combination of two or more.
- Dosage varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but usually, per adult, once per day, in the range of lmg to 100mg, once to several times a day
- Is parenteral administration preferably nasal, ophthalmic, or ointment
- a dose smaller than the above dose may be sufficient, or may be required outside the range.
- compositions When administering a compound represented by the general formula (I) or a non-toxic salt thereof, or a combination of the compound represented by the general formula (I) and another drug, a solid composition or liquid for oral administration
- a solid composition or liquid for oral administration The composition and other compositions are used as injections, external preparations, suppositories and the like for parenteral administration.
- Solid compositions for oral administration include tablets, pills, capsules, powders, granules and the like.
- Capsules include hard capsules and soft capsules.
- the one or more active substances comprise at least one inert diluent, such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, poly.
- Bulpyrrolidone is mixed with magnesium aluminate metasilicate.
- the fibrous composition may contain additives other than an inert diluent, such as a lubricant such as magnesium stearate, a disintegrant such as calcium cellulose glycolate, a stabilizer such as lactose, A dissolution aid such as glutamic acid or aspartic acid may be included.
- sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcell It may be coated with a film of a gastric or enteric substance such as low phthalate, or may be coated with two or more layers. Also included are capsules of absorbable substances, such as gelatin.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, syrups, elixirs and the like.
- the one or more active substances are contained in commonly used inert diluents (eg, purified water, ethanol).
- the composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, fragrances, and preservatives.
- compositions for oral administration include sprays which contain one or more active substances and are formulated in a manner known per se.
- the composition may contain, in addition to the inert diluent, a buffering agent that provides isotonicity with stabilizers such as sodium bisulfite, for example, isotonic agents such as sodium chloride, sodium citrate, or citric acid. You may. Methods for producing sprays are described in detail, for example, in US Pat. Nos. 2,868,691 and 3,095,355.
- Injections for parenteral administration include sterile aqueous and / or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, distilled water for injection and physiological saline.
- water-insoluble solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, and Polysorbate 80 (registered trademark).
- sterile aqueous and non-aqueous solutions, suspensions, and emulsions may be used in combination.
- compositions may further comprise a preservative, wetting agent, emulsifier, dispersant, stabilizing agent (eg, lactose), and a solubilizing agent (eg, glutamic acid, aspartic acid). May be included. These are filtered through a bacteria retention filter and disinfected. It is sterilized by combination or irradiation. They can also be used to produce sterile solid compositions, for example, dissolved in sterile or sterile distilled water for injection or other solvents before use of the lyophilized product.
- a preservative wetting agent
- emulsifier eg, dispersant
- stabilizing agent eg, lactose
- solubilizing agent eg, glutamic acid, aspartic acid
- Dosage forms of eye drops for parenteral administration include eye drops, suspension-type eye drops, emulsion-type eye drops, dissolving-type eye drops and ointments.
- eye drops are produced according to a known method.
- tonicity agents sodium chloride, concentrated glycerin, etc.
- buffering agents sodium phosphate, sodium acetate, etc.
- surfactants polysorbate 80 (trade name), stearic acid)
- Polyoxyl 40 polyoxyethylene hydrogenated castor oil, etc.
- stabilizing agents sodium citrate, sodium edetate, etc.
- preservatives benzalcoium chloride, paraben, etc.
- Inhalants for parenteral administration include aerosols, powders for inhalation, and solutions for inhalation, which are dissolved or suspended in water or other suitable medium before use. May be used.
- preservatives salts such as sodium lanthanum, paraben, etc.
- coloring agents such as sodium lanthanum, paraben, etc.
- buffering agents sodium phosphate, sodium acetate, etc.
- isotonic agents chloride
- lubricants stearic acid and its salts, etc.
- binders starch, dextrin, etc.
- excipients lactose, cellulose, etc.
- coloring agents preservatives (benzalkonium chloride, paraben) Etc.) and absorption promoters are appropriately selected and prepared as needed.
- atomizers atomizers and nebulizers
- inhalers are usually used for powders. Used.
- compositions for parenteral administration include external solutions, ointments, salves, suppositories and suppositories for rectal administration, which contain one or more active substances and are formulated in a conventional manner. Pessaries for vaginal administration are included. BEST MODE FOR CARRYING OUT THE INVENTION
- Example 1 3- (4-((2S) —4-Methyl-3,4-dihydro-2H-1,4-benzobenzoxazine-1-ylmethoxy) benzoylamino) -14-methyl pheninoleacetate Nore Estenore
- Example 1 3- (4-((2S) —4-Methyl-3,4-dihydro 2H—1,4-Benzoxazine-1-2-ylmethoxy) benzoylamino) -1-methylphenylacetate
- Example 1 3- (4-((2S) -14-methinolee 3,4-dihydro-2H-1,4-benzobenzodine-12-ylmethoxy) benzoylamino) -5-methylphenylacetic acid methinoleate
- Example 1 3- (4-((2S) —4-methinole 3,4-dihydro-2H-1,4,4-benzoxazine-1-2-ylmethoxy) benzoylamino) — 2-methyl phenylacetate methynole Esthenore
- Example 1 3- (4 -— ((2S) —4-methyl-1,4 dihydro 2H-1,4 benzoxazine-1-2-ylmethoxy) benzoylamino) —4-Hydroxypheninole acetate
- Example 1 5- (4-((2S) —4-Methyl-3,4-dihydro-1 2H-1,2,4-benzoxazine-12-ylmethoxy) penzylamino) —2-clophenylphenylene acetic acid Mechinore Esthenore
- Example 1 (9): 5- (4-((2S) —4-Methyl-3,4-dihydro-1H-2,1,4-benzoxazine-2f-methoxy) benzoylamino) —2-methyl Toxic-1-methylphenylacetate methyl ester
- Example 1 (10): 5- (4-((2S) -14-methyl-3,4-dihydro-2H-1, 4-benzoxazine-12-ylmethoxy) benzoylamino) —2-hydroxy-13-methylphenic Methinoleestenole acetate
- Example 1 (11): 3- (4 -— ((2S) —4-Methyl-3,4-dihydro-2H-1,4-benzoxazine-1-2-ylmethoxy) benzoylamino) -5-phenoxymethinoref Echinoleate acetate
- Example 1 (13): 5- (4-((2S) —4-methyl-1,4, dihydro-2H-1,4-benzotoxazine-12-inolemethoxy) benzoinoleamino) -12-fluorophenyl Acetic acid methyl ester
- Example 1 3- (4-((2S) —4-Methyl-3,4-dihydro-2H-1, 4-benzoxazine-1-2-ylmethoxy) benzoinoleamino) -5-fluoro Phenylacetic acid methyl ester
- Example 1 (15): 3— (4 — ((2S) —4-methyl-1,4-dihydro—2H—1,4-benzobenzoxazine-1 -— ”-fluoromethoxy) benzoylamino) Toximethylphenylacetic acid methyl ester
- Example 2 The compound (224 mg) produced in Example 1 was dissolved in a mixed solvent of tetrahydrofuran (2.5 mL) and methanol (2.5 mL), 2N aqueous sodium hydroxide solution (2 mL) was added, and the mixture was stirred at room temperature for 30 minutes.
- the reaction solution was concentrated under reduced pressure, and washed with t-butyl methyl ether.
- the aqueous layer was acidified with a 1N aqueous hydrochloric acid solution, and extracted with ethyl acetate.
- the organic layer was washed with saturated saline and dried over anhydrous sodium sulfate.
- Example 2 3- (4-((2S) -4-1-methyl-1,3,4-dihydro-1 2H-1,4-benzobenzodine-12-ylmethoxy) benzoylamino) -4 Noreacetic acid
- Example 2 3- (4-((2S) _4-Methyl-1,4-dihydro-12H-1,4-benzotoxazine-12-ylmethoxy) benzoylamino) —2-methylphenylacetic acid
- Example 2 3- (4-((2S) —4-Methyl-3,4-dihydro-1 2H—1,4_benzoxazine-12-ylmethoxy) benzoylamino) —4-methylphenylacetic acid
- Example 2 3- (4-((2S) _4-Methyl-3,4-dihydro 2H-1, 4-benzoxazine-1-2-ylmethoxy) benzoylamino) -5-methylphenylacetic acid
- Example 2 3- (4-((2S) -14-methyl-1,3,4-dihydro-2H-1,4-benzoxazine-1-2-ylmethoxy) benzoylamino) -5-funolelo Pheninoleacetic acid
- Example 3 The title compound having the following physical data was obtained by performing the same operation as in Example 1 using the compound prepared in Reference Example 10 instead of the compound prepared in Reference Example 9. TLC: Rf 0.20 (hexane: ethyl acetate-2: 1).
- Example 9 The same procedure as in Example 1 was carried out, except that the compound prepared in Reference Example 9 was replaced with 3- (N-methylamino) phenyl acetic acid methyl ester, to give the title compound having the following physical data.
- Example 3 Using the compound prepared in Example 3 in place of the compound prepared in Example 1, the same operation as in Example 2 was performed to obtain a title compound having the following physical properties.
- TLC: Rf0.63 (ethyl acetate: methanol 19: 1);
- Example 3 (1) Using the compound produced in Example 3 (1) in place of the compound produced in Example 1, the same operation as in Example 2 was performed to give the title compound having the following physical data. Obtained.
- Example 5 3- (2-chloro-4-((2S) -4-methyl-3,4 Dihydro- 1H- 1,4-benzoxazine-12-inolemethoxy) benzoylamino) methyl phenylacetate
- Example 5 3- (2-methyl-4-1 ((2S) -14-methyl-1,3,4-dihydro-1H-2,4-benzozozin-1-2-inolemethoxy) benzoylamino ) — 2-methylphenylacetic acid methyl ester
- Example 5 3- (2-methinole_4 — ((2S) —4-methyl-3,4—dihydro-1 2H—1,4-benzobenzoxazine-12-ylmethoxy) benzoylamino) 1-4 —Methyl phenylacetate methyl ester
- Example 5 (4): 3— (2-Methyl-4 — ((2S) —4-Methyl-1,4, -dihydro-1H-2,1,4-Benzoxazine-1-2-dimethoxy) benzoylamino) 5-fluorofluoroacetic acid methyl ester
- Example 5 5- (2-Methyl-14-((2S) -14-methyl-1,3,4-dihydro-1H-1.4H-benzoxazine-1-2-ylmethoxy) benzoinoleamino) 2-fluorophenylacetic acid methyl ester
- Example 5 5- (2-methyl-4-((2S) -14-methyl-3,4-dihydro 2H-1, 4-benzobenzoxazine-12-y ⁇ methoxy) benzoylamino) 1-2 —Methoxy acetic acid methyl ester
- Example 5 3- (2-chloro-4-1 ((2S) -4-methyl-3,4-dihydro 2H-1,4-benzobenzoxazine-1-ylmethoxy) benzoinoleamino) 14-chloro Mouth phenylacetate methyl ester
- Example 5 (8): 5- (2-chloro-1,4- (2-S) -4-methyl-3,4-dihydro-1H-2,4-benzobenzoxazine-1-ylmethoxy) benzoylamino) -1 2-phenolelophenylacetic acid methyl ester
- Example 5 3- (2-Chloro-4-1 ((2S) -4-methyl-3,4-dihydro-1H-2,4-benzobenzoxazine-1-inolemethoxy) benzoylamino) 5- Methyl phenyl acetic acid methyl ester
- Example 6 3- (2-chloro-1,4-((2S) -4-methyl-1,4, dihydro-2H-1,4-benzobenzoxazine-1,2-inolemethoxy) benzoylamino) phenylacetic acid
- Example 6 3- (2-Methynole-4-1 ((2S) —4-Methyl-13,4-dihydro-1-H-2,4-Benzoxazine-1-2-ylmethoxy) benzoylamino) -1 2-Methynolepheninoleacetic acid
- Example 6 3- (2-Methyl-4-1 ((2S) -4-methyl-3,4-dihydro-2H-1,4-benzoxazine-1-2-inolemethoxy) benzoylamino) -1-chlorophenylacetic acid
- Example 6 5- (2-Methyl-4-((2S) —4-methyl-3,4-dihydro-1H-H, 4-benzobenzoxazine-1-2- ⁇ / methoxy) benzoinoleamino) 2-Methoxyphenylacetic acid
- Example 6 3- (2-chloro-4-1 ((2S) —4-methyl_3,4 dihydro-1H-2,1—4-benzoxazine-1-2-inolemethoxy) benzo 4-amino phenylacetic acid
- Example 6 (11): 5- (2-Methyl-4-((2S) -14-methyl-3,4-dihydro-1H-2, -1,4-benzoxazine-1-2-ylmethoxy) benzylamino) 1-41 1-fluorophenylacetic acid
- Example 6 (1 3): 3- (2-chloro-1-4-((2S) -4-methyl-1,3,4-dihydro 2H-1, 4-benzoxazine-1-2-ylmethoxy) benzylamino) 1 4 monomethylphenylacetic acid
- Reference Example 13 2-Methoxy-15-aminophenylethyl acetate
- the compound prepared in Reference Example 12 25 Omg was dissolved in a mixed solvent of ethyl acetate (3 mL), methanol (3 mL) and THF (3 mL) under an argon atmosphere. Then, 10% palladium carbon (65 mg) was added, and the mixture was stirred at room temperature under a hydrogen atmosphere for 1 hour.
- Example 7 5- (4-((2S) —4-Methyl-3,4-dihydro-1 2H—1,4-benzozoxazine-12-dimethoxy) benzoinoleamino) 1-2-methoxyphenyl Ethyl acetate
- the title compound having the following physical data was obtained in the same manner as in Example 1 except that the compound produced in Reference Example 13 was used instead of the compound produced in Reference Example 9.
- TLC: Rf 0.51 (ethyl acetate: hexane 1: 1);
- Example 8 5- (4-((2S) -14-methyl-1,4, -dihydro 2H-1,4-benzobenzoxin-12-ylmethoxy) benzoylamino) 1-2-methoxyphenylacetic acid
- Example 7 (1) Using the compound prepared in Example 7 (1) instead of the compound prepared in Example 1, the same operation as in Example 2 was carried out to obtain the title compound having the following physical data.
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL16409403A IL164094A0 (en) | 2002-03-19 | 2003-03-06 | Carboxyoic acid compounds and drugs containing thecompounds as the active ingredient |
MXPA04009095A MXPA04009095A (es) | 2002-03-19 | 2003-03-06 | Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo. |
CA002479352A CA2479352A1 (en) | 2002-03-19 | 2003-03-06 | Carboxylic acid compound and a pharmaceutical agent comprising the compound as an active ingredient |
JP2003576415A JP4547913B2 (ja) | 2002-03-19 | 2003-03-06 | カルボン酸化合物およびその化合物を有効成分として含有する薬剤 |
KR10-2004-7014688A KR20040095302A (ko) | 2002-03-19 | 2003-03-06 | 카르복실산 화합물 및 그 화합물을 유효 성분으로서함유하는 약제 |
NZ535309A NZ535309A (en) | 2002-03-19 | 2003-03-06 | Carboxylic acid compounds and drugs containing the compounds as the active ingredient |
BR0308518-0A BR0308518A (pt) | 2002-03-19 | 2003-03-06 | Compostos ácidos carboxìlicos e drogas contendo os compostos como o ingrediente ativo |
AT03710260T ATE516277T1 (de) | 2002-03-19 | 2003-03-06 | Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten |
EP03710260A EP1486491B1 (en) | 2002-03-19 | 2003-03-06 | Carboxylic acid compounds and drugs containing the compounds as the active ingredient |
AU2003221325A AU2003221325A1 (en) | 2002-03-19 | 2003-03-06 | Carboxyoic acid compounds and drugs containing the compounds as the acive ingredient |
US10/507,885 US7351705B2 (en) | 2002-03-19 | 2003-03-06 | Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient |
NO20043894A NO20043894L (no) | 2002-03-19 | 2004-09-17 | Karboksysyreforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-76456 | 2002-03-19 | ||
JP2002076456 | 2002-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003078409A1 true WO2003078409A1 (fr) | 2003-09-25 |
Family
ID=28035445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/002635 WO2003078409A1 (fr) | 2002-03-19 | 2003-03-06 | Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif |
Country Status (18)
Country | Link |
---|---|
US (1) | US7351705B2 (ja) |
EP (1) | EP1486491B1 (ja) |
JP (2) | JP4547913B2 (ja) |
KR (1) | KR20040095302A (ja) |
CN (1) | CN100378083C (ja) |
AT (1) | ATE516277T1 (ja) |
AU (1) | AU2003221325A1 (ja) |
BR (1) | BR0308518A (ja) |
CA (1) | CA2479352A1 (ja) |
ES (1) | ES2365985T3 (ja) |
IL (1) | IL164094A0 (ja) |
MX (1) | MXPA04009095A (ja) |
NO (1) | NO20043894L (ja) |
NZ (1) | NZ535309A (ja) |
PL (1) | PL372466A1 (ja) |
RU (1) | RU2329256C2 (ja) |
WO (1) | WO2003078409A1 (ja) |
ZA (1) | ZA200407461B (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005028455A1 (ja) * | 2003-09-17 | 2005-03-31 | Ono Pharmaceutical Co., Ltd. | カルボン酸化合物およびそれらを有効成分として含有する医薬組成物 |
WO2006068162A1 (ja) * | 2004-12-24 | 2006-06-29 | Shionogi & Co., Ltd. | 慢性閉塞性肺疾患の治療剤 |
WO2007037187A1 (ja) * | 2005-09-27 | 2007-04-05 | Shionogi & Co., Ltd. | Pgd2受容体アンタゴニスト活性を有するスルホンアミド誘導体 |
US7241792B2 (en) | 2004-12-23 | 2007-07-10 | Arena Pharmaceuticals, Inc. | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof |
WO2007149312A2 (en) | 2006-06-16 | 2007-12-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
US7321001B2 (en) | 2002-12-20 | 2008-01-22 | Amgen Inc. | Asthma and allergic inflammation modulators |
WO2009022687A1 (ja) * | 2007-08-10 | 2009-02-19 | Ono Pharmaceutical Co., Ltd. | フェニル酢酸化合物 |
EP2116244A1 (en) | 2003-05-15 | 2009-11-11 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
JP2011502969A (ja) * | 2007-11-02 | 2011-01-27 | グラクソ グループ リミテッド | 新規化合物 |
US8183293B2 (en) | 2007-12-19 | 2012-05-22 | Amgen Inc. | Phenyl acetic acid derivatives |
US8507473B2 (en) | 2008-09-11 | 2013-08-13 | Arena Pharmaceuticals, Inc. | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders |
US8637555B2 (en) | 2003-10-31 | 2014-01-28 | Arena Pharmaceuticals, Inc. | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
WO2020059790A1 (ja) | 2018-09-20 | 2020-03-26 | 小野薬品工業株式会社 | Dpアンタゴニスト |
JPWO2021187547A1 (ja) * | 2020-03-19 | 2021-09-23 | ||
JP2021151996A (ja) * | 2020-03-19 | 2021-09-30 | 小野薬品工業株式会社 | フェニル酢酸化合物を含有する医薬組成物 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070244107A1 (en) * | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
CN101056635A (zh) * | 2004-11-04 | 2007-10-17 | 默克公司 | 烟酸受体激动剂、含有该化合物的组合物及治疗方法 |
US20070299122A1 (en) * | 2004-11-08 | 2007-12-27 | Tobert Jonathan A | Method of Treating Pathological Blushing |
EP1824812A4 (en) * | 2004-11-23 | 2009-10-28 | Merck & Co Inc | AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES |
CA2598273A1 (en) * | 2005-02-17 | 2006-08-24 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
WO2008097535A2 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
RU2015151129A (ru) * | 2009-10-08 | 2019-01-15 | Санофи | Производные фенилоксадиазола в качестве ингибиторов pgds |
CN113748103A (zh) * | 2019-04-26 | 2021-12-03 | 日产化学株式会社 | 芳基磺酸酯化合物的制造方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986005779A1 (en) * | 1985-04-03 | 1986-10-09 | Yamanouchi Pharmaceutical Co., Ltd. | Phenylene derivatives |
WO1998025919A1 (en) * | 1996-12-13 | 1998-06-18 | Shionogi & Co., Ltd. | Benzothiophenecarboxamide derivatives and pgd2 antagonists comprising them |
WO2001066520A1 (fr) * | 2000-03-09 | 2001-09-13 | Ono Pharmaceutical Co., Ltd. | Derives indole, procede de preparation de ces derives et leur utilisation |
-
2003
- 2003-03-06 RU RU2004130837/04A patent/RU2329256C2/ru not_active IP Right Cessation
- 2003-03-06 ES ES03710260T patent/ES2365985T3/es not_active Expired - Lifetime
- 2003-03-06 US US10/507,885 patent/US7351705B2/en not_active Expired - Fee Related
- 2003-03-06 JP JP2003576415A patent/JP4547913B2/ja not_active Expired - Fee Related
- 2003-03-06 AU AU2003221325A patent/AU2003221325A1/en not_active Abandoned
- 2003-03-06 MX MXPA04009095A patent/MXPA04009095A/es active IP Right Grant
- 2003-03-06 WO PCT/JP2003/002635 patent/WO2003078409A1/ja active Application Filing
- 2003-03-06 KR KR10-2004-7014688A patent/KR20040095302A/ko not_active Application Discontinuation
- 2003-03-06 BR BR0308518-0A patent/BR0308518A/pt not_active IP Right Cessation
- 2003-03-06 EP EP03710260A patent/EP1486491B1/en not_active Expired - Lifetime
- 2003-03-06 CA CA002479352A patent/CA2479352A1/en not_active Abandoned
- 2003-03-06 NZ NZ535309A patent/NZ535309A/en unknown
- 2003-03-06 PL PL03372466A patent/PL372466A1/xx not_active Application Discontinuation
- 2003-03-06 IL IL16409403A patent/IL164094A0/xx unknown
- 2003-03-06 AT AT03710260T patent/ATE516277T1/de not_active IP Right Cessation
- 2003-03-06 CN CNB03811495XA patent/CN100378083C/zh not_active Expired - Fee Related
-
2004
- 2004-09-16 ZA ZA200407461A patent/ZA200407461B/en unknown
- 2004-09-17 NO NO20043894A patent/NO20043894L/no not_active Application Discontinuation
-
2010
- 2010-04-30 JP JP2010105565A patent/JP5168315B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986005779A1 (en) * | 1985-04-03 | 1986-10-09 | Yamanouchi Pharmaceutical Co., Ltd. | Phenylene derivatives |
WO1998025919A1 (en) * | 1996-12-13 | 1998-06-18 | Shionogi & Co., Ltd. | Benzothiophenecarboxamide derivatives and pgd2 antagonists comprising them |
WO2001066520A1 (fr) * | 2000-03-09 | 2001-09-13 | Ono Pharmaceutical Co., Ltd. | Derives indole, procede de preparation de ces derives et leur utilisation |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7321001B2 (en) | 2002-12-20 | 2008-01-22 | Amgen Inc. | Asthma and allergic inflammation modulators |
US7541383B2 (en) | 2002-12-20 | 2009-06-02 | Amgen Inc. | Asthma and allergic inflammation modulators |
EP2286816A1 (en) | 2003-05-15 | 2011-02-23 | Merck Sharp & Dohme (I.A.) Corp. | Method of treating atherosclerosis, dyslipidemias and related conditions |
EP2116244A1 (en) | 2003-05-15 | 2009-11-11 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
WO2005028455A1 (ja) * | 2003-09-17 | 2005-03-31 | Ono Pharmaceutical Co., Ltd. | カルボン酸化合物およびそれらを有効成分として含有する医薬組成物 |
US8138335B2 (en) | 2003-09-17 | 2012-03-20 | Ono Pharmaceutical Co., Ltd | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
US7601712B2 (en) | 2003-09-17 | 2009-10-13 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
US8637555B2 (en) | 2003-10-31 | 2014-01-28 | Arena Pharmaceuticals, Inc. | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
US7241792B2 (en) | 2004-12-23 | 2007-07-10 | Arena Pharmaceuticals, Inc. | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof |
US7612106B2 (en) | 2004-12-23 | 2009-11-03 | Arena Pharmaceuticals, Inc. | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof |
WO2006068162A1 (ja) * | 2004-12-24 | 2006-06-29 | Shionogi & Co., Ltd. | 慢性閉塞性肺疾患の治療剤 |
JP5114202B2 (ja) * | 2005-09-27 | 2013-01-09 | 塩野義製薬株式会社 | Pgd2受容体アンタゴニスト活性を有するスルホンアミド誘導体 |
EP2407453A1 (en) | 2005-09-27 | 2012-01-18 | Shionogi & Co., Ltd. | PGD2 receptor antagonist |
WO2007037187A1 (ja) * | 2005-09-27 | 2007-04-05 | Shionogi & Co., Ltd. | Pgd2受容体アンタゴニスト活性を有するスルホンアミド誘導体 |
WO2007149312A2 (en) | 2006-06-16 | 2007-12-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
EP3175856A1 (en) | 2006-06-16 | 2017-06-07 | The Trustees of the University of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss |
US9254293B2 (en) | 2006-06-16 | 2016-02-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH |
JP5083319B2 (ja) * | 2007-08-10 | 2012-11-28 | 小野薬品工業株式会社 | フェニル酢酸化合物 |
US8318729B2 (en) | 2007-08-10 | 2012-11-27 | Ono Pharmaceutical Co., Ltd. | Phenylacetic acid compound |
JP2012229247A (ja) * | 2007-08-10 | 2012-11-22 | Ono Pharmaceut Co Ltd | フェニル酢酸化合物 |
US8476266B2 (en) | 2007-08-10 | 2013-07-02 | Ono Pharmaceutical Co., Ltd. | Phenylacetic acid compound |
AU2008287784B2 (en) * | 2007-08-10 | 2012-08-02 | Ono Pharmaceutical Co., Ltd. | Phenylacetic acid compound |
US8809524B2 (en) | 2007-08-10 | 2014-08-19 | Ono Pharmaceutical Co., Ltd. | Phenylacetic acid compound |
KR101464799B1 (ko) | 2007-08-10 | 2014-11-27 | 오노 야꾸힝 고교 가부시키가이샤 | 페닐아세트산 화합물 |
WO2009022687A1 (ja) * | 2007-08-10 | 2009-02-19 | Ono Pharmaceutical Co., Ltd. | フェニル酢酸化合物 |
JP2011502969A (ja) * | 2007-11-02 | 2011-01-27 | グラクソ グループ リミテッド | 新規化合物 |
US8183293B2 (en) | 2007-12-19 | 2012-05-22 | Amgen Inc. | Phenyl acetic acid derivatives |
US8507473B2 (en) | 2008-09-11 | 2013-08-13 | Arena Pharmaceuticals, Inc. | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders |
WO2020059790A1 (ja) | 2018-09-20 | 2020-03-26 | 小野薬品工業株式会社 | Dpアンタゴニスト |
KR20210065944A (ko) | 2018-09-20 | 2021-06-04 | 오노 야꾸힝 고교 가부시키가이샤 | Dp 길항제 |
JPWO2020059790A1 (ja) * | 2018-09-20 | 2021-09-02 | 小野薬品工業株式会社 | Dpアンタゴニスト |
JP7021709B2 (ja) | 2018-09-20 | 2022-02-17 | 小野薬品工業株式会社 | Dpアンタゴニスト |
US11319296B2 (en) | 2018-09-20 | 2022-05-03 | Ono Pharmaceutical Co., Ltd. | DP antagonist |
KR102425709B1 (ko) | 2018-09-20 | 2022-07-28 | 오노 야꾸힝 고교 가부시키가이샤 | Dp 길항제 |
KR20220107330A (ko) | 2018-09-20 | 2022-08-02 | 오노 야꾸힝 고교 가부시키가이샤 | Dp 길항제 |
JP7338711B2 (ja) | 2018-09-20 | 2023-09-05 | 小野薬品工業株式会社 | Dpアンタゴニスト |
JPWO2021187547A1 (ja) * | 2020-03-19 | 2021-09-23 | ||
WO2021187547A1 (ja) * | 2020-03-19 | 2021-09-23 | 小野薬品工業株式会社 | フェニル酢酸化合物の結晶 |
JP2021151996A (ja) * | 2020-03-19 | 2021-09-30 | 小野薬品工業株式会社 | フェニル酢酸化合物を含有する医薬組成物 |
JP7047954B2 (ja) | 2020-03-19 | 2022-04-05 | 小野薬品工業株式会社 | フェニル酢酸化合物を含有する医薬組成物 |
JP7088411B2 (ja) | 2020-03-19 | 2022-06-21 | 小野薬品工業株式会社 | フェニル酢酸化合物の結晶 |
Also Published As
Publication number | Publication date |
---|---|
JP5168315B2 (ja) | 2013-03-21 |
RU2004130837A (ru) | 2005-05-27 |
JP2010189431A (ja) | 2010-09-02 |
US7351705B2 (en) | 2008-04-01 |
KR20040095302A (ko) | 2004-11-12 |
MXPA04009095A (es) | 2004-12-06 |
AU2003221325A1 (en) | 2003-09-29 |
IL164094A0 (en) | 2005-12-18 |
ES2365985T3 (es) | 2011-10-14 |
ATE516277T1 (de) | 2011-07-15 |
NZ535309A (en) | 2006-05-26 |
JP4547913B2 (ja) | 2010-09-22 |
EP1486491A4 (en) | 2006-02-15 |
CN1656085A (zh) | 2005-08-17 |
CN100378083C (zh) | 2008-04-02 |
EP1486491A1 (en) | 2004-12-15 |
CA2479352A1 (en) | 2003-09-25 |
ZA200407461B (en) | 2005-07-01 |
US20050222216A1 (en) | 2005-10-06 |
JPWO2003078409A1 (ja) | 2005-07-14 |
PL372466A1 (en) | 2005-07-25 |
RU2329256C2 (ru) | 2008-07-20 |
NO20043894L (no) | 2004-12-17 |
BR0308518A (pt) | 2005-02-22 |
EP1486491B1 (en) | 2011-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003078409A1 (fr) | Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif | |
RU2416601C2 (ru) | Соединение индола и его применение | |
WO2016041489A1 (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
JPWO2004078719A1 (ja) | インドール誘導体化合物およびその化合物を有効成分とする薬剤 | |
JPWO2003022814A1 (ja) | インドール誘導体化合物 | |
KR101464799B1 (ko) | 페닐아세트산 화합물 | |
US20100029631A1 (en) | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | |
JPH05506455A (ja) | ロイコトリエンd↓4拮抗剤としてのキノリニル―ベンゾヘテロ二環式誘導体 | |
WO2004065365A1 (ja) | 8−アザプロスタグランジン誘導体およびその医薬用途 | |
JP2006515596A (ja) | Pparデルタ活性化化合物として用いられるインドールフェニルスルホンアミド誘導体 | |
JP2006511522A (ja) | N−(インドールエチル)シクロアミン化合物 | |
WO2017183723A1 (ja) | Kcnq2~5チャネル活性化剤 | |
KR101152495B1 (ko) | 카르복실산 화합물 및 이들을 유효 성분으로서 함유하는의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003576415 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 164094 Country of ref document: IL Ref document number: 535309 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003710260 Country of ref document: EP Ref document number: 2479352 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/07461 Country of ref document: ZA Ref document number: 200407461 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 372466 Country of ref document: PL Ref document number: 1020047014688 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/009095 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003221325 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004130837 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047014688 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003811495X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003710260 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10507885 Country of ref document: US |